Diaceutics finds 156K cancer patients could miss out on life-saving drugs every year in US and Europe Diaceutics, the medtech company enabling better patient testing globally, today announces research results showing that more than 156,000 cancer patients in the US and Europe could be missing out on targeted life-saving drugs every year due to suboptimal diagnostic testing – therefore potentially affecting their chances of survival. Diaceutics has also found that substandard testing practices are causing pharmaceutical companies in the US and Europe to miss out on up to $16.6 billion in potential revenues annually.
May-2017 | Press Releases
Personalized Medicine (PM) Connective Announces Achievement of Several Milestones May-2017 | Press Releases
Diaceutics signs multi-million-euro partnership with BioReference Laboratories to improve patient outcomes Apr-2017 | Press Releases
Diaceutics announces 30 jobs on back of 60% revenue growth Apr-2017 | Press Releases

Media Mentions

Precision testing for patients is undergoing a revolution Aug-2017 | Media Mentions
156K cancer patients could miss out on life-saving drugs every year in US and Europe May-2017 | Media Mentions
Irish medtech company Diaceutics to recruit 30 people Apr-2017 | Media Mentions